SH2D1B

Summary

SH2D1B (SH2 domain containing 1B, HGNC:30416) is a protein-coding gene on chromosome 1q23.3, encoding SH2 domain-containing protein 1B (O14796). Cytoplasmic adapter regulating receptors of the signaling lymphocytic activation molecule (SLAM) family such as CD84, SLAMF1, LY9 and CD244.

By binding phosphotyrosines through its free SRC (MIM 190090) homology-2 (SH2) domain, EAT2 regulates signal transduction through receptors expressed on the surface of antigen-presenting cells (Morra et al., 2001 [PubMed 11689425]).

Source: NCBI Gene 117157 — RefSeq curated summary.

At a glance

• GWAS associations: 3
• Clinical variants (ClinVar): 20 total
• MANE Select transcript: NM_053282

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:30416
Approved symbol	SH2D1B
Name	SH2 domain containing 1B
Location	1q23.3
Locus type	gene with protein product
Status	Approved
Aliases	EAT2
Ensembl gene	ENSG00000198574
Ensembl biotype	protein_coding
OMIM	608510
Entrez	117157

Gene structure

Transcript identifiers

Ensembl transcripts: 3 — 2 protein_coding, 1 retained_intron

ENST00000367929, ENST00000493550, ENST00000852031

RefSeq mRNA: 1 — MANE Select: NM_053282 NM_053282

CCDS: CCDS30928

Canonical transcript exons

ENST00000367929 — 4 exons

Exon	Start	End
ENSE00001201242	162402739	162402802
ENSE00001227609	162398923	162399087
ENSE00001425016	162395268	162397315
ENSE00001510901	162411883	162412136

Expression profiles

Bgee: expression breadth ubiquitous, 153 present calls, max score 93.14.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 1.3150 / max 482.1776, expressed in 160 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
15673	1.2370	152
201793	0.0398	13
15672	0.0382	18

Top tissues by expression

234 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
granulocyte	CL:0000094	93.14	gold quality
gastrocnemius	UBERON:0001388	81.05	gold quality
blood	UBERON:0000178	80.46	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	79.44	gold quality
leukocyte	CL:0000738	79.26	gold quality
muscle of leg	UBERON:0001383	79.22	gold quality
sperm	CL:0000019	78.43	gold quality
hindlimb stylopod muscle	UBERON:0004252	78.09	gold quality
monocyte	CL:0000576	77.95	gold quality
amniotic fluid	UBERON:0000173	77.45	gold quality
deltoid	UBERON:0001476	75.29	gold quality
esophagus squamous epithelium	UBERON:0006920	74.62	gold quality
spleen	UBERON:0002106	73.60	gold quality
buccal mucosa cell	CL:0002336	72.70	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	71.78	gold quality
lower esophagus mucosa	UBERON:0035834	70.58	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	69.59	silver quality
biceps brachii	UBERON:0001507	69.24	silver quality
endothelial cell	CL:0000115	68.95	silver quality
skeletal muscle tissue	UBERON:0001134	68.01	gold quality
muscle tissue	UBERON:0002385	65.50	gold quality
vastus lateralis	UBERON:0001379	64.31	silver quality
colonic epithelium	UBERON:0000397	64.13	silver quality
quadriceps femoris	UBERON:0001377	63.79	silver quality
bone marrow cell	CL:0002092	62.85	silver quality
bone marrow	UBERON:0002371	62.61	gold quality
upper lobe of left lung	UBERON:0008952	61.27	gold quality
right lung	UBERON:0002167	61.22	gold quality
epithelium of nasopharynx	UBERON:0001951	61.11	silver quality
lymph node	UBERON:0000029	60.53	gold quality

Single-cell (SCXA)

Detected in 4 experiment(s), a significant marker in 4.

Experiment	Marker?	Max mean expression
E-GEOD-70580	yes	957.91
E-CURD-122	yes	51.93
E-MTAB-6678	yes	31.89
E-ANND-3	yes	25.06

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

109 targeting SH2D1B, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4425	100.00	67.59	1049
HSA-MIR-4795-3P	100.00	74.62	4024
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-4803	99.98	71.99	3117
HSA-MIR-3065-5P	99.97	71.56	3281
HSA-MIR-548AB	99.95	71.31	3488
HSA-MIR-559	99.95	72.28	3609
HSA-MIR-23A-3P	99.95	74.24	3163
HSA-MIR-23B-3P	99.95	74.24	3163
HSA-MIR-23C	99.95	73.92	3192
HSA-MIR-6845-3P	99.94	66.88	1439
HSA-MIR-548A-5P	99.94	71.27	3482
HSA-MIR-548AD-5P	99.94	71.23	3502
HSA-MIR-548AE-5P	99.94	71.23	3502
HSA-MIR-548AK	99.94	71.24	3488
HSA-MIR-548AM-5P	99.94	71.24	3488
HSA-MIR-548AP-5P	99.94	71.14	3489
HSA-MIR-548AQ-5P	99.94	71.34	3426
HSA-MIR-548AR-5P	99.94	71.28	3515
HSA-MIR-548AS-5P	99.94	71.22	3482
HSA-MIR-548AU-5P	99.94	71.24	3488
HSA-MIR-548AY-5P	99.94	71.23	3502
HSA-MIR-548B-5P	99.94	71.23	3502
HSA-MIR-548BB-5P	99.94	71.27	3509
HSA-MIR-548C-5P	99.94	71.24	3488
HSA-MIR-548D-5P	99.94	71.23	3502
HSA-MIR-548H-5P	99.94	71.24	3488
HSA-MIR-548I	99.94	71.25	3481
HSA-MIR-548J-5P	99.94	71.14	3489

Literature-anchored findings (GeneRIF, showing 4)

• NTB-A-mediated IFN-gamma production was greatly reduced in the absence of SLAM-associated protein (SAP), demonstrating that cytokine production and cytotoxicity are differentially dependent on SAP and possibly EAT-2 (PMID:16920955)
• Data indicate that Ewing’s sarcoma-associated transcript-2 (EAT-2) over-expression increased the anti-tumor activity of NK cells against K562 tumor cell. targets. (PMID:24374770)
• EAT-2 mediates its effects in natural killer cells by linking SLAM family receptors to phospholipase Cgamma, calcium fluxes, and Erk kinase. (PMID:24687958)
• When compared with SAP, the other single SH2 domain protein in human, EAT2 shows similar binding energies to unphosphorylated ligands. This is inconsistent to the previous data showing low affinity of EAT2 toward unphosphorylated peptides compared to SAP which shows high affinity (PMID:27586300)

Cross-species orthologs

10 orthologs

Organism	Symbol	Gene ID
danio_rerio	inppl1b	ENSDARG00000001442
mus_musculus	Sh2d1b2	ENSMUSG00000073494
mus_musculus	Sh2d1b1	ENSMUSG00000102418
rattus_norvegicus	Sh2d1b2	ENSRNOG00000069420
drosophila_melanogaster	CG9784	FBGN0030761
drosophila_melanogaster	CG6805	FBGN0034179
drosophila_melanogaster	Synj	FBGN0034691
drosophila_melanogaster	sp3	FBGN0038890
caenorhabditis_elegans		WBGENE00006763
caenorhabditis_elegans	sac-2	WBGENE00012353

Paralogs (13): SYNJ2 (ENSG00000078269), FIG4 (ENSG00000112367), OCRL (ENSG00000122126), INPP5K (ENSG00000132376), INPP5E (ENSG00000148384), SYNJ1 (ENSG00000159082), INPPL1 (ENSG00000165458), INPP5D (ENSG00000168918), SH2D1A (ENSG00000183918), INPP5J (ENSG00000185133), INPP5F (ENSG00000198825), INPP5B (ENSG00000204084), SACM1L (ENSG00000211456)

Protein

Protein identifiers

SH2 domain-containing protein 1B — O14796 (reviewed: O14796)

Alternative names: EWS/FLI1-activated transcript 2

All UniProt accessions (1): O14796

UniProt curated annotations — full annotation on UniProt →

Function. Cytoplasmic adapter regulating receptors of the signaling lymphocytic activation molecule (SLAM) family such as CD84, SLAMF1, LY9 and CD244. In SLAM signaling seems to cooperate with SH2D1A/SAP. Plays a role in regulation of effector functions of natural killer (NK) cells by controlling signal transduction through CD244/2B4 without effecting its tyrosine phosphorylation; downstream signaling involves PLCG1 and ERK activation. Activation of SLAMF7-mediated NK cell function does not effect receptor tyrosine phosphorylation but distal signaling. In the context of NK cell-mediated cytotoxicity does not enhance conjugate formation with target cells but stimulates polarization of the microtubule-organizing center and cytotoxic granules toward the NK cell synapse. Negatively regulates CD40-induced cytokine production in dendritic cells downstream of SLAM family receptors probably by inducing activation of the PI3K pathway to inhibit p38 MAPK and JNK activation.

Subunit / interactions. Binds to the phosphorylated receptors CD84, SLAMF1, LY9 and CD244. Does not bind to non-phosphorylated SLAMF1. Interacts with SLAMF7 (via ITSM phosphorylated on ‘Tyr-304’). Interacts with Src kinases HCK, LYN, FYN, FGR and LCK (via kinase domains). Interacts (phosphorylated at Tyr-127) with PLCG1.

Isoforms (2)

UniProt ID	Names	Canonical?
O14796-1	1	yes
O14796-2	2

RefSeq proteins (1): NP_444512* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000980	SH2	Domain
IPR035049	EAT2_SH2	Domain
IPR036860	SH2_dom_sf	Homologous_superfamily

Pfam: PF00017

UniProt features (16 total): strand 7, helix 2, sequence variant 2, chain 1, domain 1, modified residue 1, splice variant 1, mutagenesis site 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
5KAZ	X-RAY DIFFRACTION	1.7

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-O14796-F1	80.44	0.61

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 127

Mutagenesis-validated functional residues (1):

Position	Phenotype
127	no stimulation of granule polarization during nk-mediated cytotoxicity, abolishes activation of cd244/2b4-mediated cytot

Function

Pathways and Gene Ontology

Reactome pathways

3 pathways

ID	Pathway
R-HSA-198933	Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
R-HSA-1280218	Adaptive Immune System
R-HSA-168256	Immune System

MSigDB gene sets: 117 (showing top): GSE18804_BRAIN_VS_COLON_TUMORAL_MACROPHAGE_DN, REACTOME_ADAPTIVE_IMMUNE_SYSTEM, GOBP_LEUKOCYTE_MEDIATED_IMMUNITY, GOBP_CELL_ACTIVATION_INVOLVED_IN_IMMUNE_RESPONSE, GOBP_POSITIVE_REGULATION_OF_RESPONSE_TO_EXTERNAL_STIMULUS, GOBP_REGULATION_OF_IMMUNE_RESPONSE, GOBP_DEFENSE_RESPONSE_TO_OTHER_ORGANISM, GOBP_LYMPHOCYTE_MEDIATED_IMMUNITY, ROZANOV_MMP14_TARGETS_UP, GOBP_REGULATION_OF_RESPONSE_TO_STRESS, GOBP_REGULATION_OF_LYMPHOCYTE_MEDIATED_IMMUNITY, TGANTCA_AP1_C, GOBP_ADAPTIVE_IMMUNE_RESPONSE, GOBP_NATURAL_KILLER_CELL_MEDIATED_IMMUNITY, GOBP_POSITIVE_REGULATION_OF_RESPONSE_TO_BIOTIC_STIMULUS

GO Biological Process (6): adaptive immune response (GO:0002250), leukocyte activation involved in immune response (GO:0002366), positive regulation of natural killer cell mediated immunity (GO:0002717), innate immune response (GO:0045087), positive regulation of innate immune response (GO:0045089), immune system process (GO:0002376)

GO Molecular Function (2): protein-macromolecule adaptor activity (GO:0030674), protein binding (GO:0005515)

GO Cellular Component (1): cytosol (GO:0005829)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
Adaptive Immune System	1
Immune System	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
immune response	3
cell activation involved in immune response	1
leukocyte activation	1
natural killer cell mediated immunity	1
positive regulation of lymphocyte mediated immunity	1
regulation of natural killer cell mediated immunity	1
positive regulation of innate immune response	1
defense response to symbiont	1
positive regulation of response to biotic stimulus	1
positive regulation of defense response	1
positive regulation of response to external stimulus	1
innate immune response	1
regulation of innate immune response	1
positive regulation of immune response	1
biological_process	1
protein binding	1
molecular adaptor activity	1
binding	1
cytoplasm	1
cellular anatomical structure	1

Protein interactions and networks

STRING

734 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
SH2D1B	LY9	Q9HBG7	937
SH2D1B	CD84	Q9UIB8	936
SH2D1B	CD244	Q9BZW8	864
SH2D1B	SLAMF1	Q13291	824
SH2D1B	SLAMF6	Q96DU3	813
SH2D1B	SLAMF7	Q9NQ25	783
SH2D1B	EIF4A1	P04765	777
SH2D1B	PTPN11	Q06124	760
SH2D1B	CD2	P06729	755
SH2D1B	EWSR1	Q01844	682
SH2D1B	EIF4A2	Q14240	662
SH2D1B	FYN	P06241	612
SH2D1B	KLRC2	P26717	603
SH2D1B	CD48	P09326	543
SH2D1B	SLAMF9	Q96A28	541

IntAct

99 interactions, top by confidence:

A	B	Type	Score
TRIM54	SH2D1B	psi-mi:“MI:0915”(physical association)	0.720
SH2D1B	TRIM54	psi-mi:“MI:0915”(physical association)	0.720
SH2D1B	CD244	psi-mi:“MI:0407”(direct interaction)	0.690
CD244	SH2D1B	psi-mi:“MI:0914”(association)	0.690
SH2D1B	CD244	psi-mi:“MI:0915”(physical association)	0.690
SLAMF6	SH2D1B	psi-mi:“MI:0914”(association)	0.620
SH2D1B	SLAMF6	psi-mi:“MI:0915”(physical association)	0.620
	SH2D1B	psi-mi:“MI:0915”(physical association)	0.570
SH2D1B		psi-mi:“MI:0915”(physical association)	0.570
SH2D1B	TCF12	psi-mi:“MI:0915”(physical association)	0.560
SH2D1B	DDIT4L	psi-mi:“MI:0915”(physical association)	0.560
BLK	SH2D1B	psi-mi:“MI:0915”(physical association)	0.560
SH2D1B	AGR2	psi-mi:“MI:0915”(physical association)	0.560
	SH2D1B	psi-mi:“MI:0915”(physical association)	0.560
SH2D1B	MEOX2	psi-mi:“MI:0915”(physical association)	0.560
SH2D1B	TNK2	psi-mi:“MI:0915”(physical association)	0.560
SH2D1B	BLK	psi-mi:“MI:0915”(physical association)	0.560

BioGRID (35): SH2D1B (Two-hybrid), HSPA1A (Two-hybrid), STAT4 (Two-hybrid), SH2D1B (Two-hybrid), OLIG1 (Two-hybrid), PTK2 (Two-hybrid), HSPA1A (Affinity Capture-Luminescence), OLIG1 (Affinity Capture-Luminescence), SH2D1B (Two-hybrid), SH2D1B (Two-hybrid), SH2D1B (Two-hybrid), SH2D1B (Two-hybrid), SH2D1B (Two-hybrid), SH2D1B (Two-hybrid), SH2D1B (Two-hybrid)

ESM2 similar proteins: B2RZ59, O12990, O14543, O14796, O35324, O35718, O60880, O88583, O88890, O88900, P05433, P08487, P0CE43, P10686, P19174, P43403, P43404, P43405, P46108, P46109, P47941, P81718, P87378, P97504, Q00655, Q04929, Q06AA1, Q09178, Q14449, Q22070, Q2I6J0, Q3ZBB1, Q45HK4, Q5ICW4, Q5U2U2, Q60760, Q62077, Q62120, Q62689, Q63768

Diamond homologs: A0A8I3NFE2, A0FI79, A0JNB0, A1Y2K1, A6QLK6, B2RZ59, B5KFD7, D3ZGS3, D7PF45, F1RDG9, G5ECJ6, O14306, O14796, O15357, O35324, O60880, O88890, O88900, P00519, P00520, P00521, P00522, P03949, P06239, P06241, P09851, P0CE43, P10447, P17713, P20936, P29350, P29351, P32019, P34370, P39688, P42684, P42685, P42686, P50904, P53356

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 32 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Constitutive Signaling by Aberrant PI3K in Cancer	6	34.6×	4e-06
PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling	6	26.4×	1e-05
PIP3 activates AKT signaling	6	18.2×	5e-05
RAF/MAP kinase cascade	6	16.7×	6e-05
Signaling by Receptor Tyrosine Kinases	5	11.7×	8e-04

GO biological processes:

GO term	Partners	Fold	FDR
epidermal growth factor receptor signaling pathway	6	46.5×	1e-06
adaptive immune response	5	13.2×	3e-03
immune response	6	8.8×	3e-03
intracellular signal transduction	6	7.2×	6e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

20 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	17
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

573 predictions. Top by Δscore:

Variant	Effect	Δscore
1:162411881:A:AC	donor_gain	1.0000
1:162411882:C:CC	donor_gain	1.0000
1:162411882:CGAGA:C	donor_gain	1.0000
1:162411952:T:TA	donor_gain	1.0000
1:162397311:CTGTT:C	acceptor_gain	0.9900
1:162402800:AACCT:A	acceptor_loss	0.9900
1:162402801:ACCTG:A	acceptor_loss	0.9900
1:162402804:T:G	acceptor_loss	0.9900
1:162402805:G:C	acceptor_loss	0.9900
1:162411877:ACTCA:A	donor_loss	0.9900
1:162411878:CTCA:C	donor_loss	0.9900
1:162411879:T:TG	donor_loss	0.9900
1:162411880:CAC:C	donor_loss	0.9900
1:162411881:ACGAG:A	donor_loss	0.9900
1:162411882:CG:C	donor_gain	0.9900
1:162411882:CGAG:C	donor_gain	0.9900
1:162397318:T:C	acceptor_gain	0.9800
1:162398922:C:CT	donor_gain	0.9800
1:162411882:CGA:C	donor_gain	0.9800
1:162398955:T:A	donor_gain	0.9700
1:162399003:C:CT	donor_gain	0.9700
1:162402733:TCTTA:T	donor_loss	0.9700
1:162402734:CTTA:C	donor_loss	0.9700
1:162402735:TTAC:T	donor_loss	0.9700
1:162402736:TACC:T	donor_loss	0.9700
1:162402737:A:C	donor_loss	0.9700
1:162402738:C:CT	donor_loss	0.9700
1:162411973:CAGT:C	donor_gain	0.9700
1:162397316:C:CC	acceptor_gain	0.9600
1:162398896:TTCTG:T	donor_gain	0.9600

AlphaMissense

860 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
1:162411924:T:A	R31S	0.989
1:162411924:T:G	R31S	0.989
1:162411933:A:C	F28L	0.988
1:162411933:A:T	F28L	0.988
1:162411935:A:G	F28L	0.988
1:162411931:A:G	L29P	0.984
1:162411918:G:C	S33R	0.983
1:162411918:G:T	S33R	0.983
1:162411920:T:G	S33R	0.983
1:162411940:C:T	G26D	0.983
1:162411940:C:A	G26V	0.982
1:162399041:A:G	L82P	0.980
1:162411925:C:G	R31T	0.980
1:162402788:A:T	V50D	0.978
1:162411892:A:G	L42P	0.978
1:162411894:G:C	C41W	0.978
1:162411925:C:A	R31I	0.977
1:162411886:A:T	V44D	0.976
1:162411890:A:G	C43R	0.975
1:162399058:A:C	F76L	0.974
1:162399058:A:T	F76L	0.974
1:162399060:A:G	F76L	0.974
1:162411896:A:G	C41R	0.974
1:162411928:A:G	L30S	0.973
1:162411888:A:C	C43W	0.970
1:162402776:C:G	R54P	0.969
1:162411931:A:T	L29H	0.969
1:162411972:A:C	C15W	0.969
1:162402773:A:G	I55T	0.967
1:162402773:A:C	I55S	0.966

dbSNP variants (sampled 300 via entrez): RS1000210350 (1:162405214 A>C,G), RS1000229443 (1:162408937 A>G), RS1000231526 (1:162402539 A>C,G), RS1000384990 (1:162398932 T>A,C), RS1000645036 (1:162397153 T>C), RS1000716869 (1:162397564 C>A,T), RS1000948032 (1:162403660 T>C), RS1000949588 (1:162407338 C>G), RS1000980586 (1:162410040 G>T), RS1001013030 (1:162409713 G>A), RS1001831173 (1:162402061 G>A,C,T), RS1002216423 (1:162402357 A>C), RS1002317549 (1:162395237 T>G), RS1002390978 (1:162395706 A>G), RS1002611658 (1:162402466 C>A,G,T)

Disease associations

OMIM: gene MIM:608510 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

3 associations (top):

Study	Trait	p-value
GCST006575_29	Takayasu arteritis	2.000000e-07
GCST010538_3	Sum of carotid plaque area	5.000000e-06
GCST010539_2	Sum of stenosis	4.000000e-07

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0006501	carotid plaque build

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

15 total (human), top 15 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
triphenyl phosphate	affects expression	1
butyraldehyde	increases expression	1
di-n-butylphosphoric acid	affects expression	1
CGP 52608	affects binding, increases reaction	1
(+)-JQ1 compound	decreases expression	1
Zoledronic Acid	increases expression	1
Air Pollutants, Occupational	decreases expression	1
Arsenic	affects expression	1
Benzo(a)pyrene	affects methylation, increases methylation	1
Estradiol	affects cotreatment, decreases expression	1
Nickel	decreases expression	1
Progesterone	affects cotreatment, decreases expression	1
Tobacco Smoke Pollution	increases expression	1
Aflatoxin B1	increases methylation	1
Okadaic Acid	increases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.